当地时间12月14日，诺和诺德宣布，其大股东诺和控股以165亿美元收购美国合同制药商康泰伦特（Catalent）相关的所有监管交割条件均已满足，双方现在可自由完成交易，以及诺和诺德随后从诺和控股收购三个康泰伦特制造基地。诺和诺德预计收购将在未来几天完成。今年2月，诺和控股宣布，将以全现金交易形式收购康泰伦特，加上债 ...

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected ...

(RTTNews) - Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close ...

MNC在中美市场打响新一轮自建产能保卫战，留给CDMO的增量订单正在减少。 阿斯利康首席执行官Pascal ...

Catalent Inc. (CTLT)股价已达到显著的52周高点，触及62.51美元，因为该公司继续在制药和生物技术解决方案板块乘势上涨。市值113亿美元的Catalent，根据 InvestingPro ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

继《生物安全法案》阉割落幕之后，改变全球生物制药CDMO格局的另一重磅事件在本月迎来“终局之战”，12月7日，诺和控股165亿美元收购Catalent已获欧盟无条件批准。这通常表明欧盟委员会经过详细调查后，认为该并购交易不会对市场竞争造成负面影响，因 ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Catalent Inc. (CTLT)股价已达到显著的52周新高，触及61.68美元，市值达111.5亿美元。根据 InvestingPro 分析，该股票似乎正在其公允价值之上交易，而分析师目标价表明可能上涨至63.50美元。这一里程碑反映了自去年以来的显著上升趋势，过去12个月股票回报率达53%，今年至今更是实现了36.72%的impressive涨幅。股价升至52周新高凸显了市场对Catal ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...